Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Intercept Pharmaceuticals Inc
Net Change in Cash
Intercept Pharmaceuticals Inc
Net Change in Cash Peer Comparison
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
|
Net Change in Cash
-$16.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-21%
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
$11.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$218m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$21.9B
|
CAGR 3-Years
-140%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$126.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Intercept Pharmaceuticals Inc's Net Change in Cash?
Net Change in Cash
-16.5m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Net Change in Cash amounts to -16.5m USD.
What is Intercept Pharmaceuticals Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
-21%
The average annual Net Change in Cash growth rates for Intercept Pharmaceuticals Inc have been -12% over the past three years , 23% over the past five years , and -21% over the past ten years .